Concurrent Chemoradiotherapy in Curatively Resected Gallbladder Carcinoma: A Propensity Score-Matched Analysis
Autor: | Benxing Gu, Xiaonan Sun, Jingjing Shan, Qi Wang, Jian-Bin Hu, Hai Liu, Hong Yu, Xiujun Cai, Qichu Yang, Xiao Liang, Liwen Qian, Liming Shi |
---|---|
Rok vydání: | 2017 |
Předmět: |
Adult
Male Cancer Research medicine.medical_specialty Time Factors medicine.medical_treatment Matched-Pair Analysis Kaplan-Meier Estimate Gastroenterology Disease-Free Survival 03 medical and health sciences 0302 clinical medicine Interquartile range Internal medicine Antineoplastic Combined Chemotherapy Protocols medicine Carcinoma Humans Radiology Nuclear Medicine and imaging Stage (cooking) Propensity Score Aged Retrospective Studies Aged 80 and over Radiation business.industry Gallbladder Retrospective cohort study Chemoradiotherapy Middle Aged medicine.disease Surgery Radiation therapy medicine.anatomical_structure Oncology 030220 oncology & carcinogenesis Propensity score matching Cohort Multivariate Analysis Feasibility Studies Lymph Node Excision Regression Analysis 030211 gastroenterology & hepatology Female Gallbladder Neoplasms business |
Zdroj: | International journal of radiation oncology, biology, physics. 100(1) |
ISSN: | 1879-355X |
Popis: | Purpose To compare overall survival (OS) between patients receiving radical resection followed by concurrent chemoradiotherapy (S+CCRT) and patients receiving radical resection only (S) for advanced resectable gallbladder carcinoma (GBC). Methods and Materials Ninety-four GBC patients with stage pT2-4, N0-1, and M0 consented to inclusion in a clinical database from June 2003 to July 2013. Patients who received S+CCRT were matched by propensity score with those who received S through nearest-neighbor matching, with a caliper width of 0.2 to ensure similar baseline characteristics between each group. The effects of CCRT on OS and disease-free survival (DFS) were evaluated with Kaplan-Meier analysis. Cox proportional hazards regression was performed on the entire cohort. Adverse effects and oncologic outcomes were assessed. Results Seventy-eight patients with GBC (39 S+CCRT; 39 S) were matched according to propensity score; the 1-year, 3-year, and 5-year OS was 74.4%, 56.4%, and 42.4% for the S+CCRT group and 51.3%, 30.8%, and 17.9% for the S group. The median survival time was 27 months (interquartile range [IQR], 12-58 months) for the S+CCRT group versus 13 months (IQR, 5-30 months) for the S group ( P =.004), with the 1-year and 3-year DFS being 59.0% versus 35.9% and 48.7% versus 13.5%, respectively, and the median DFS being 23 months (IQR, 8-57 months) versus 7 months (IQR, 4-23 months) ( P =.004). Conclusions The OS of matched patients with stage II-IVA GBC is significantly improved by CCRT. Radiation therapy combined with single-agent or dual-agent chemotherapy was feasible and well tolerated. |
Databáze: | OpenAIRE |
Externí odkaz: |
načítá se...